imidapril 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
angiotensin-converting enzyme inhibitors 1424 89371-37-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • imidapril hydrochloride
  • tanatril
  • imidapril
  • TA-6366
  • imidapril HCl
  • Molecular weight: 405.45
  • Formula: C20H27N3O6
  • CLOGP: 1.53
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 2
  • TPSA: 116.25
  • ALOGS: -2.96
  • ROTB: 10

Drug dosage:

DoseUnitRoute
10 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 5 % Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability) 20 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1993 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cardiac failure 46.84 37.90 20 478 76020 50528606

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cerebral infarction 35.94 29.91 16 769 24659 29549083

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cardiac failure 61.37 28.66 38 1446 132335 64364913
Cerebral infarction 51.54 28.66 23 1461 41021 64456227
Hepatic function abnormal 50.21 28.66 26 1458 64287 64432961
Renal impairment 41.38 28.66 30 1454 134987 64362261
Interstitial lung disease 37.64 28.66 25 1459 97707 64399541
Embolic stroke 31.90 28.66 10 1474 6701 64490547

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C09AA16 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, PLAIN
ACE inhibitors, plain
MeSH PA D000806 Angiotensin-Converting Enzyme Inhibitors
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011480 Protease Inhibitors
CHEBI has role CHEBI:35457 ACE inhibitor
CHEBI has role CHEBI:35674 antihypertensive drugs
CHEBI has role CHEBI:50266 Prodrugs
CHEBI has role CHEBI:49103 drug metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.49 acidic
pKa2 4.83 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Angiotensin-converting enzyme Enzyme INHIBITOR IC50 5 CHEMBL SCIENTIFIC LITERATURE

External reference:

IDSource
D01549 KEGG_DRUG
89396-94-1 SECONDARY_CAS_RN
C0165703 UMLSCUI
CHEBI:135654 CHEBI
CHEBI:141520 CHEBI
CHEMBL317094 ChEMBL_ID
DB11783 DRUGBANK_ID
C065166 MESH_SUPPLEMENTAL_RECORD_UI
5464343 PUBCHEM_CID
6377 IUPHAR_LIGAND_ID
C078006 MESH_SUPPLEMENTAL_RECORD_UI
6378 IUPHAR_LIGAND_ID
6394 INN_ID
89371-44-8 SECONDARY_CAS_RN
BW7H1TJS22 UNII
5464344 PUBCHEM_CID
259335 RXNORM
007791 NDDF
007792 NDDF
395741003 SNOMEDCT_US
395984005 SNOMEDCT_US
426163004 SNOMEDCT_US
C0246977 UMLSCUI
CHEMBL99701 ChEMBL_ID
7209 INN_ID
WUU07Y30IA UNII

Pharmaceutical products:

None